1st Quarter - Report

340B HEALTH for 340B HEALTH

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$181,501
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 21, 2008 $181,501 Replaced
1st Quarter - Report Feb 18, 2009 $181,501 Replaced
1st Quarter - Amendment Feb 19, 2009 $181,501 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

HR 2606 and S 1376: Extending 340B Drug Pricing to Inpatient Drugs and improving program integrity Preserving current 340B Patient Definition Opposition to new regulations regarding physician administered drugs

LobbyistCovered position, as disclosed
MARISA SCHRADER CONWAY New —
ANNA MANGUM Leg Assistant for Rep. Visclosky and Fascel
EDITH MARSHALL (No longer employed by organization
JONNI MCCRANN (No longer employed by organization)
ROBERT RECKLAUS New Chief of Staff for Rep. Carolyn McCarthy (NY-4)
TED SLAFSKY Fellow for Sen. Democratic Policy Comm
WILLIAM VON OEHSEN —
COURTNEY YOHE (No longer employed by organization)

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2606 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.